Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 325-337 , June 2009

Treatment and outcomes of large vessel arteritis

  • Frances A. Borg, BMBCh, MA, MRCP (Locum Consultant in Rheumatology)
    • ,
  • Bhaskar Dasgupta, MBBS, MD, FRCP (Consultant Rheumatologist and Honorary Professor of Health and Human Sciences)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 1702 385252; Fax: +44 1702 385909.

References 

  1. Liu NH, LaBree LD, Feldon SE, et al. The epidemiology of giant cell arteritis. Ophthalmology. 2001;108:1145–1149
  2. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919–929
  3. Vanoli M, Daina E, Salvarani C, et al. Takayasu's arteritis: a study of 104 Italian patients. Arthritis Rheum. 2005;53(1):100–107
  4. Park MC, Lee SW, Park YB, et al. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol. 2005;34:284–292
  5. Maksimowicz-McKinnon K, Clark TM, Hoffmann GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu Arteritis patients. Arthritis Rheum. 2007;56(3):1000–1007
  6. Subramanyan R, Joy J, Balakrishnan KG. Natural history of aortoarteritis (Takayasu's disease). Circulation. 1989;80(3):429–437
  7. Mwipatayi BP, Jeffery PC, Beningfield SJ, et al. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg. 2005;75:110–117
  8. Ureten K, Ozturk MA, Onat AM, et al. Takayasu's arteritis: results of a university hospital of 45 patients in Turkey. Int J Cardiol. 2004;96:259–264
  9. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine. 2000;79(5):283–292
  10. Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005;53(2):293–297
  11. Loddenkemper T, Pankaj P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry. 2007;78:1255–1259
  12. Nesher G, Berkun Y, Mates M, et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine. 2004;83:114–122
  13. Galor A, Lee MS. Slowly progressive vision loss in giant cell arteritis. Arch Ophthal. 2006;124:416–418
  14. Danesh-Meyer H, Franzco , Savino PJ, et al. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005;112:1098–1103
  15. Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003;110:1204–1215
  16. Smetana GW, Shmerling RH. Does this patient have temporal arteritis?. JAMA. 2002;287(1):92–101
  17. Makkuni D, Bharadwaj A, Wolfe K, et al. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis?. Rheumatology. 2008;47(4):488–490
  18. Nuenninghoff DM, Hunder GG, Christianson TJH, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis. Arthritis Rheum. 2003;48(12):3522–3531
  19. Shelhamer JH, Volkman DJ, Parrillo JE, et al. Takayasu's arteritis and its therapy. Ann Intern Med. 1985;103:121–126
  20. Boyev LR, Miller NR, Green WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol. 1999;128(2):211–215
  21. Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?. Ann Intern Med. 1994;120(12):987–992
  22. Ray-Chaudhuri N, Ah Kine D, Tijani SO, et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002;86:530–532
  23. Narvaez J, Narvaez JJ, Nolla JM, et al. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology. 2005;44:479–483
  24. Bley TA, Uhl M, Carew J, et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol. 2007;28:1722–1727
  25. Bley TA, Markl M, Schlep M, et al. Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment. Rheumatology. 2008;47:65–67
  26. Hata A, Numano F. Magnetic resonance imaging of vascular changes in Takayasu arteritis. Int J Cardiol. 1995;52:45–52
  27. Tso E, Flamm SD, White RD, et al. Takayasu's arteritis. Utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum. 2002;46(6):1634–1642
  28. Webb M, Chambers A, Al-Nahhas A, et al. The role of 18FDG-PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging. 2004;31(5):627–634
  29. Walter M, Melzer RA, Schindler C, et al. The value of [18F]FDG-PET in the diagnosis of large vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. 2005;32:674–681
  30. Meller K, Grabbe E, Becker W, Vosshenrich R. Value of F-18 FDG hybrid camera PET and MRI in early Takayasu aortitis. Eur Radiol. 2003;13:400–405
  31. Turlakow A, Yeung HWD, Pui J, et al. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med. 2001;161:1003–1007
  32. Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55(1):131–137
  33. Schmidt WA, Kraft HE, Vorpahl , et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337(19):1337–1342
  34. Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JPA. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005;142:359–369
  35. Raninen RO, Kupari MM, Pamilo MS, et al. Ultrasonography in the quantification of arterial involvement in Takayasu's arteritis. Scand J Rheumatol. 2000;29:56–61
  36. Park SH, Chung JW, Lee JW, et al. Carotid artery involvement in Takayasu's arteritis. J Ultrasound Med. 2001;20:371–378
  37. Heyreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Acta Ophthalmol Scand. 2002;80:353–367
  38. Proven A, Gabriel SK, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703–708
  39. Chan CCK, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85:1061–1064
  40. Faroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003;110:539–542
  41. Chevalet P, Barrier J-H, Pottier P, et al. A randomized multi-center controlled trial using intravenous pulses if Methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients. J Rheumatol. 2000;27:1481–1491
  42. Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids. Arthritis Rheum. 2006;54(10):3310–3318
  43. Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant cell arteritis with methotrexate and prednisone. Ann Intern Med. 2001;134:106–114
  44. Hoffman GS, Cid MC, Helklmann DB, et al. A multicentre randomized double blind placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309–1318
  45. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–2797
  46. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double blind study. Ann Rheum Dis. 1986;45:136–138
  47. Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr. 2007;150(1):72–76
  48. Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu artertitis with methotrexate. Arthritis Rheum. 1994;37(4):578–582
  49. Valsakumar AK, Chirammal Valappil U, Jorapor V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol. 2003;30(8):1793–1798
  50. Shinjo SK, Pereira RMR, Tizziani VAP, et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol. 2007;26:1871–1875
  51. Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis. Ann Intern Med. 1999;130:422–426
  52. Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu's arteritis. Arthritis Rheum. 2004;50(7):2296–2304
  53. Karageorgaki ZT, Mavragni CP, Papathanasiou MA, et al. Infliximab in Takyasu arteritis: a safe alternative?. Clin Rheumatol. 2007;26:984–987
  54. Tato F, Rieger K, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol. 2005;24(3):304–307
  55. Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab. Arthritis Rheum. 2001;44(12):2933–2935
  56. Andonopoulos AP, Meimaris N, Daoussis D, et al. Experience with infliximab (anti-TNFα monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis. 2003;62:1116
  57. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. Ann Intern Med. 2007;146:631–639
  58. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med. 2007;146:621–630
  59. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2007;(epub 17 Dec 2007)
  60. Bhatia A, Ell PJ, Edwards JCW. Anti-CD20 monoclonal antibody (Rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005;64:1099–1100
  61. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischaemic complications in giant cell arteritis. Arthritis Rheum. 2004;50(4):1332–1337
  62. Weaver FA, Kumar SR, Yellin AE, et al. Renal revascularisation in Takayasu arteritis-induced renal artery stenosis. J Vasc Surg. 2004;39:749–757
  63. Fields CE, Bower TC, Cooper LT, et al. Takayasu's arteritis: operative results and influence of disease activity. J Vasc Surg. 2006;43:64–71
  64. Park MC, Lee SW, Park YB, et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology. 2006;45:600–605
  65. Sharma BK, Jain S, Bali HK, et al. A follow-up study of balloon angioplasty and de-novo stenting in Takayasu arteritis. Int J Cardiol. 2000;75:S147–S152
  66. Min P-K, Park S, Jung J-H, et al. Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with Takayasu's arteritis. J Endovasc Ther. 2005;12:23–34
  67. Miyata T, Sato O, Koyama H, et al. Long-term survival after surgical treatment of patients with Takayasu's arteritis. Circulation. 2003;108:1474–1480
  68. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85(3):327–331
  69. Neunninghoff DM, Hunder GG, Christianson TJH, et al. Mortality of large-artery complications (aortic aneurysm, aortic dissection and/or large-artery stenosis) in patients with giant cell arteritis. Arthritis Rheum. 2003;48(12):3532–3537

PII: S1521-6942(09)00042-4

doi: 10.1016/j.berh.2009.04.001

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 325-337 , June 2009

Article Tools